ORAL Surveillance update! Composite ischemic CV/HF risk not numerically different w/ tofa vs TNFi. In pts w/ ASCVD hx, MACE endpoints were numerically higher w/ tofa. CV risk was higher w/ tofa 10 mg BID vs TNFi. Check out CIs! Abs L06 #ACR22 @RheumNow https://t.co/XXTsU4el66 https://t.co/WvFqziKVkT
Links:
Risk of Extended Major Adverse Cardiovascular Event Endpoints with Tofacitinib …
http://ow.ly/QML650LsuA3
14-11-2022